Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Considering the options in the 2020 election, the pharma industry would probably vote for a split ticket: Joe Biden for President and Mitch McConnell for Senate majority leader, an outcome that would eliminate mercurial executive tweets on drug pricing, but retain a congressional bulwark against damaging pricing legislation.
But a Biden presidency would bring with it the threat of aggressive executive action on drug pricing – assuming any...
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.
Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.
